GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, jumped 5% through 9:55 a.m. ET Monday on a series of positive announcements for its GLP-1 products.

The maker of Ozempic is cutting the price of the drug nearly in half for some patients. Novo Nordisk had already cut the price of Wegovy, a medication with the same active ingredient that's approved for weight loss.

Novo Nordisk launches a new cash-pay option for a leading diabetes drug, changing affordability dynamics for uninsured patients across the U.S.